Full Text Journal Articles about
Vnar

Advertisement

Find full text journal articles






Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.

Aziz Gauhar, Cyril V Privezentzev, Mykhaylo Demydchuk, Tanja Gerlza, Julia Rieger, Andreas J Kungl, Frank S Walsh, J Lynn Rutkowski, Pawel Stocki,

Single domain shark variable domain of new antigen receptor (VNAR) antibodies can offer a viable alternative to conventional Ig-based monoclonal antibodies in treating COVID-19 disease during the current pandemic. Here we report the identification of neutralizing single domain VNAR antibodies selected against the severe acute respiratory syndrome coronavirus 2 spike ... Read more >>

FASEB J (FASEB journal : official publication of the Federation of American Societies for Experimental Biology)
[2021, 35(11):e21970]

Cited: 0 times

View full text PDF listing >>



Shark New Antigen Receptor (IgNAR): Structure, Characteristics and Potential Biomedical Applications.

Salma Nassor Juma, Xiaoxia Gong, Sujie Hu, Zhengbing Lv, Jianzhong Shao, Lili Liu, Guiqian Chen,

Shark is a cartilaginous fish that produces new antigen receptor (IgNAR) antibodies. This antibody is identified with a similar human heavy chain but dissimilar sequences. The variable domain (VNAR) of IgNAR is stable and small in size, these features are desirable for drug discovery. Previous study results revealed the effectiveness ... Read more >>

Cells (Cells)
[2021, 10(5):]

Cited: 0 times

View full text PDF listing >>



Advertisement

Topological and Structural Plasticity of the Single Ig Fold and the Double Ig Fold Present in CD19.

Philippe Youkharibache,

The Ig fold has had a remarkable success in vertebrate evolution, with a presence in over 2% of human genes. The Ig fold is not just the elementary structural domain of antibodies and TCRs, it is also at the heart of a staggering 30% of immunologic cell surface receptors, making ... Read more >>

Biomolecules (Biomolecules)
[2021, 11(9):]

Cited: 0 times

View full text PDF listing >>



Shark Antibody Variable Domains Rigidify Upon Affinity Maturation-Understanding the Potential of Shark Immunoglobulins as Therapeutics.

Monica L Fernández-Quintero, Clarissa A Seidler, Patrick K Quoika, Klaus R Liedl,

Sharks and other cartilaginous fish are the phylogenetically oldest living organisms that have antibodies as part of their adaptive immune system. As part of their humoral adaptive immune response, they produce an immunoglobulin, the so-called immunoglobulin new antigen receptor (IgNAR), a heavy-chain only antibody. The variable domain of an IgNAR, ... Read more >>

Front Mol Biosci (Frontiers in molecular biosciences)
[2021, 8:639166]

Cited: 0 times

View full text PDF listing >>



Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.

Eduardo Ruiz-López, Alberto J Schuhmacher,

Single-domain antibodies derive from the heavy-chain-only antibodies of <i>Camelidae</i> (camel, dromedary, llama, alpaca, vicuñas, and guananos; i.e., nanobodies) and cartilaginous fishes (i.e., VNARs). Their small size, antigen specificity, plasticity, and potential to recognize unique conformational epitopes represent a diagnostic and therapeutic opportunity for many central nervous system (CNS) pathologies. However, ... Read more >>

Biomolecules (Biomolecules)
[2021, 11(8):]

Cited: 0 times

View full text PDF listing >>



A novel PD-L1-targeted shark VNAR single domain-based CAR-T strategy for treating breast cancer and liver cancer

Dan Li, Hejiao English, Jessica Hong, Tianyuzhou Liang, Glenn Merlino, Chi-Ping Day, Mitchell Ho,

Chimeric antigen receptor (CAR)-T cell therapy shows great potency against hematological malignancies, whereas it remains difficult to treat solid tumors mainly due to lack of appropriate antigenic targets and immunosuppressive tumor microenvironment (TME). Checkpoint molecule PD-L1 is widely overexpressed on multiple tumor types, and the PD-1/PD-L1 interaction is a key ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.

Arturo Macarrón Palacios, Julius Grzeschik, Lukas Deweid, Simon Krah, Stefan Zielonka, Thies Rösner, Matthias Peipp, Thomas Valerius, Harald Kolmar,

The B-cell receptor (BCR) is a key player of the adaptive immune system. It is a unique part of immunoglobulin (Ig) molecules expressed on the surface of B cells. In case of many B-cell lymphomas, the tumor cells express a tumor-specific and functionally active BCR, also known as idiotype. Utilizing ... Read more >>

Front Immunol (Frontiers in immunology)
[2020, 11:560244]

Cited: 1 time

View full text PDF listing >>



Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.

Pawel Stocki, Jaroslaw Szary, Charlotte L M Rasmussen, Mykhaylo Demydchuk, Leandra Northall, Diana Bahu Logan, Aziz Gauhar, Laura Thei, Torben Moos, Frank S Walsh, J Lynn Rutkowski,

Transfer across the blood-brain barrier (BBB) remains a significant hurdle for the development of biopharmaceuticals with therapeutic effects within the central nervous system. We established a functional selection method to identify high affinity single domain antibodies to the transferrin receptor 1 (TfR1) with efficient biotherapeutic delivery across the BBB. A ... Read more >>

FASEB J (FASEB journal : official publication of the Federation of American Societies for Experimental Biology)
[2021, 35(2):e21172]

Cited: 6 times

View full text PDF listing >>



Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR.

Elodie Pothin, Dominique Lesuisse, Pierre Lafaye,

Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of ... Read more >>

Pharmaceutics (Pharmaceutics)
[2020, 12(10):]

Cited: 2 times

View full text PDF listing >>



Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.

Edurne Rujas, Hong Cui, Taylor Sicard, Anthony Semesi, Jean-Philippe Julien,

The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade. ... Read more >>

Nat Commun (Nature communications)
[2020, 11(1):5066]

Cited: 2 times

View full text PDF listing >>



Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle.

Dag Sehlin, Pawel Stocki, Tobias Gustavsson, Greta Hultqvist, Frank S Walsh, J Lynn Rutkowski, Stina Syvänen,

Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single domain shark antibody VNAR fragment (TXB2) with similar affinity to murine and human TfR1 was used to shuttle protein cargo into the brain. TXB2 was ... Read more >>

FASEB J (FASEB journal : official publication of the Federation of American Societies for Experimental Biology)
[2020, 34(10):13272-13283]

Cited: 4 times

View full text PDF listing >>



Strategic Development of an Immunotoxin for the Treatment of Glioblastoma and Other Tumours Expressing the Calcitonin Receptor.

Pragya Gupta, David L Hare, Peter J Wookey,

New strategies aimed at treatment of glioblastoma are frequently proposed to overcome poor prognosis. Recently, research has focused on glioma stem cells (GSCs), some quiescent, which drive expansion of glioblastoma and provide the complexity and heterogeneity of the tumour hierarchy. Targeting quiescent GSCs is beyond the capability of conventional drugs ... Read more >>

Cells (Cells)
[2021, 10(9):]

Cited: 0 times

View full text PDF listing >>



Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature.

Adam Leach, Peter Smyth, Laura Ferguson, John Steven, Michelle K Greene, Cristina M Branco, Aidan P McCann, Andrew Porter, Caroline J Barelle, Christopher J Scott,

Whilst there is an extensive body of preclinical nanomedicine research, translation to clinical settings has been slow. Here we present a novel approach to the targeted nanoparticle (NP) concept: utilizing both a novel targeting ligand, VNAR (Variable New Antigen Receptor), a shark-derived single chain binding domain, and an under-investigated target ... Read more >>

Nanoscale (Nanoscale)
[2020, 12(27):14751-14763]

Cited: 2 times

View full text PDF listing >>



The White-Spotted Bamboo Shark Genome Reveals Chromosome Rearrangements and Fast-Evolving Immune Genes of Cartilaginous Fish.

Yaolei Zhang, Haoyang Gao, Hanbo Li, Jiao Guo, Bingjie Ouyang, Meiniang Wang, Qiwu Xu, Jiahao Wang, Meiqi Lv, Xinyu Guo, Qun Liu, Likun Wei, Han Ren, Yang Xi, Yang Guo, Bingzhao Ren, Shanshan Pan, Chuxin Liu, Xiaoyan Ding, Haitao Xiang, Yingjia Yu, Yue Song, Lingfeng Meng, Shanshan Liu, Jun Wang, Yuan Jiang, Jiahai Shi, Shiping Liu, Jamal S M Sabir, Mumdooh J Sabir, Muhummadh Khan, Nahid H Hajrah, Simon Ming-Yuen Lee, Xun Xu, Huanming Yang, Jian Wang, Guangyi Fan, Naibo Yang, Xin Liu,

Chondrichthyan (cartilaginous fish) occupies a key phylogenetic position and is important for investigating evolutionary processes of vertebrates. However, limited whole genomes impede our in-depth knowledge of important issues such as chromosome evolution and immunity. Here, we report the chromosome-level genome of white-spotted bamboo shark. Combing it with other shark genomes, ... Read more >>

iScience (iScience)
[2020, 23(11):101754]

Cited: 3 times

View full text PDF listing >>



Immunogenicity and humanization of single-domain antibodies.

Martin A Rossotti, Kasandra Bélanger, Kevin A Henry, Jamshid Tanha,

Single-domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy-chain antibodies, have many desirable properties as components of biologic drugs. However, their sequences may increase the risk of immunogenicity and antidrug antibody (ADA) development in humans, and thus, sdAbs are routinely humanized during development. Here, we review and ... Read more >>

FEBS J (The FEBS journal)
[2021, :]

Cited: 3 times

View full text PDF listing >>



High-efficacy, high-manufacturability human VH domain antibody therapeutics from transgenic sources.

Kasandra Bélanger, Jamshid Tanha,

Interest in single-domain antibodies (sdAbs) stems from their unique structural/pronounced, hence therapeutically desirable, features. From the outset-as therapeutic modalities-human antibody heavy chain variable domains (VHs) attracted a particular attention compared with 'naturally-occurring' camelid and shark heavy-chain-only antibody variable domains (VHHs and VNARs, respectively) due to their perceived lack of immunogenicity. ... Read more >>

Protein Eng Des Sel (Protein engineering, design & selection : PEDS)
[2021, 34:]

Cited: 0 times

View full text PDF listing >>



[Progress in shark single-domain antibody].

Xing Liu, Qi Chen,

Monoclonal antibody (mAb) is an important biological macromolecule and widely used in immune detection, in vitro diagnostics, and drug discovery. However, the inherent properties of mAb restrict its further development, such as high molecular weight and complex structure. Therefore, there is an urgent need to develop alternatives for mAb. Various ... Read more >>

Sheng Wu Gong Cheng Xue Bao (Sheng wu gong cheng xue bao = Chinese journal of biotechnology)
[2020, 36(6):1069-1082]

Cited: 1 time

View full text PDF listing >>



Proof of long-term immunological memory in cartilaginous fishes.

Oliver Eve, Hanover Matz, Helen Dooley,

Immunological memory provides long-term protection against pathogen re-infection and is the foundation for successful vaccination. We have previously shown an antigen-specific recall response in nurse sharks almost one year after primary exposure. Herein, we extend the time between prime and successful recall to >8 years, the longest period for which ... Read more >>

Dev Comp Immunol (Developmental and comparative immunology)
[2020, 108:103674]

Cited: 2 times

View full text PDF listing >>



Diagnostic and therapeutic potential of shark variable new antigen receptor (VNAR) single domain antibody.

Wei Shien Cheong, Chiuan Yee Leow, Abu Bakar Abdul Majeed, Chiuan Herng Leow,

Conventional monoclonal antibodies (mAbs) have been widely used in research and diagnostic applications due to their high affinity and specificity. However, multiple limitations, such as large size, complex structure and sensitivity to extreme ambient temperature potentially weaken the performance of mAbs in certain applications. To address this problem, the exploration ... Read more >>

Int J Biol Macromol (International journal of biological macromolecules)
[2020, 147:369-375]

Cited: 4 times

View full text PDF listing >>



In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties.

John Steven, Obinna C Ubah, Magdalena Buschhaus, Marina Kovaleva, Laura Ferguson, Andrew J Porter, Caroline J Barelle,

VNAR domains are the binding regions of new antigen receptor proteins (IgNAR) which are unique to sharks, skates, and rays (Elasmobranchii). Individual VNAR domains can bind antigens independently and are the smallest reported adaptive immune recognition entities in the vertebrate kingdom. Sharing limited sequence homology with human immunoglobulin domains, their ... Read more >>

Methods Mol Biol (Methods in molecular biology (Clifton, N.J.))
[2020, 2070:115-142]

Cited: 0 times

View full text PDF listing >>



Isolation of highly selective IgNAR variable single-domains against a human therapeutic Fc scaffold and their application as tailor-made bioprocessing reagents.

Magdalena J Buschhaus, Stefan Becker, Andrew J Porter, Caroline J Barelle,

The adaptive immune system of cartilaginous fish (Elasmobranchii), comprising of classical hetero-tetrameric antibodies, is enhanced through the presence of a naturally occurring homodimeric antibody-like immunoglobulin-the new antigen receptor (IgNAR). The binding site of the IgNAR variable single-domain (VNAR) offers advantages of reduced size (<1/10th of classical immunoglobulin) and extended binding ... Read more >>

Protein Eng Des Sel (Protein engineering, design & selection : PEDS)
[2019, 32(9):385-399]

Cited: 0 times

View full text PDF listing >>



In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development.

Obinna C Ubah, Andrew J Porter, Caroline J Barelle,

Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster anti-hTNF-α monoclonal antibodies is well recognised, especially for adalimumab and infliximab treatments, with the large and complex molecular architecture of ... Read more >>

J Immunol Res (Journal of immunology research)
[2020, 2020:7283239]

Cited: 1 time

View full text PDF listing >>



Blood-brain barrier transport using a high-affinity, brain-selective VNAR (Variable Domain of New Antigen Receptor) antibody targeting transferrin receptor 1

Pawel Stocki, Jaroslaw Szary, Charlotte LM Rasmussen, Mykhaylo Demydchuk, Leandra Northall, Diana Bahu Logan, Aziz Gauhar, Laura Thei, Torben Moos, Frank Walsh, Lynn Rutkowski,

<h4>ABSTRACT</h4> Transfer across the blood-brain barrier (BBB) remains a significant hurdle for the development of biopharmaceuticals with therapeutic effects within the central nervous system. We established a functional selection method to identify high-affinity single domain antibodies to the transferrin receptor 1 (TfR1) with efficient biotherapeutic delivery across the BBB. <h4>Methods</h4> ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Summarizing the extent of visit irregularity in longitudinal data.

Armend Lokku, Lily S Lim, Catherine S Birken, Eleanor M Pullenayegum, ,

<h4>Background</h4>Observational longitudinal data often feature irregular, informative visit times. We propose descriptive measures to quantify the extent of irregularity to select an appropriate analytic outcome approach.<h4>Methods</h4>We divided the study period into bins and calculated the mean proportions of individuals with 0, 1, and > 1 visits per bin. Perfect repeated measures features ... Read more >>

BMC Med Res Methodol (BMC medical research methodology)
[2020, 20(1):135]

Cited: 0 times

View full text PDF listing >>



Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand.

Kathryn L Pepple, Leslie Wilson, Russell N Van Gelder, Marina Kovaleva, Obinna C Ubah, John Steven, Caroline J Barelle, Andrew Porter,

<h4>Purpose</h4>We assess the efficacy of two next-generation biologic therapies in treating experimental autoimmune uveitis.<h4>Methods</h4>Variable binding domains from shark immunoglobulin novel antigen receptors (VNARs) were fused with a mouse IgG2a constant domain (Fc) to generate VNAR-Fc molecules with binding specificity to tumor necrosis factor alpha (TNFα) or inducible T-cell costimulatory ligand ... Read more >>

Transl Vis Sci Technol (Translational vision science & technology)
[2019, 8(5):11]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.1119 s